Clinical evaluation of Cefotiam hexetil in acute tosillitis

• Published in: OTOLOGIA FUKUOKA Vol. 35; no. 1; pp. 65 - 81
• Main Authors: KAWAMURA Shozo, TSUIKI Takashi, SHISHIDO Kiyoshi, NEMOTO Satohiko, MURAKAWA Yasuko, TAKASAKA Tomonori, SHINKAWA Hideichi, IKEDA Katsuhisa, SUZUKI Hideaki, ONODERA Akira, KANBAYASHI Junichi, ENDO Satomi, ITABASHI Takatsugu, WATANABE Hiroshi, FUJIMAKI Yutaka, OGURA Shuji, ICHIKAWA Tomoya, MIYAKE Hirosato, SHINKAWA Atsushi, SAKAI Makoto, NAKAYAMA Mutsumi, SAKAMOTO Yutaka, TSUCHIHASHI Nobuaki, ISOBE Ikuko, OGAWA Shigeo, MURAKAMI Yoshihiko, SATOMURA Hiroshi, BABA Shunkichi, KASAZIMA Tetsuya, HATANO Tsutomu, KINOSHITA Haruji, OHYA Yasuhiko, TSUKIYAMA Masao, YOKOTA Akira, WADA Masaki, MARUO Takeshi, ITO Haruo, TAKANO Tsuyoshi, KAWAI Takashi, IWATA Shigenobu, NAITO Masao, SAKAKURA Yasuo, SAKAKURA Kenji, MATSUNAGA Toru, OKUMURA Ryuji, ICHIYOSHI Mikiko, SAKAI Kunio, FURUKAWA Hiroshi, TAMAKI Hiromitsu, HASEGAWA Satoshi, ISHIDA Minoru, TAYA Naozo, NOIRI Teruhisa, SHINDO Shojiro, MIYAMOTO Hiroaki, MOMODA Eizo, INATOME Kinichi, HAGA Minoru, HARADA Yasuo, YAJIN Koji, TAGASHIRA Nobuharu, HIRAKAWA Katsuhiro, KUROKAWA Michinori, TAKANO Akira, MURAKAMI Yuzuru, OHYA Takako, SUGATA Yoshinori, TAKEBAYASHI Shubun, KISHIMOTO Akinori, KIKUYA Yoshinori, CHIKUIE Daisuke, YANAGIHARA Naoaki, GYO Kiyofumi, SUGITA Toshiaki, MOGI Goro, KURONO Yuichi, TOMONAGA Kazuhiro, KUGA Masaaki, YUMISAKI Akiteru, OHYAMA Masaru, FURUTA Shigeru, FUKAMI Kozo, SHIMA Tetsuya, YANO Hiromi, OHNO Ikuo, HIROTA Joji, UCHIZONO Akihiro, OHBORI Yasuichi, NAKASHIMA Mitsuyoshi, DEGUCHI Koichi
• Format: Journal Article
• Language: Japanese
• Published: JIBI TO RINSHO KAI 1989
• Subjects: acute tonsillitis; cefaclor; Cefotiam hexetil; double blind comparative study
• ISSN: 0447-7227
• DOI: 10.11334/jibi1954.35.1_65

Cefotiam hexetil (CTM-HE) was evaluated for its efficacy, safety and usefulness in acute tonsillitis, in a double blind manner using cefaclor (CCL) as a control drug. The drug was orally administered after each meal, as a rule, for consecutive 7 days (CTM-HE: 200mg×3/day, CCL: 250mg×3/day). Out of the 231 patients recruited in this trial, 192 (99 on CTM-HE and 93 on CCL) were adopted by the committee for the evaluation of therapeutic efficacy. 1. The clinical responses judged by the attending physicians were positive in 91.9% of the patients on CTM-HE and 88.2% of the patients on CCL (commitee's judgement: 88.9% on CTM-HE, 86.0% on CCL). 2. The bacteriological responses were assessed as “eradicated” in 95.7% of the patients on CTM-HE and 97.6% of the patients on CCL. 3. Adverse events, mainly mild or moderate gastrointestinal tract symptoms, were observed in 7.5% (8/107) of the patients on CTM-HE, and in 4.0% (4/100) of the patients on CCL. No abnormal alterations of laboratory findings were noted in any groups. 4. The usefulness was rated as “very useful” and “fairly useful” in 91.0% of the patients on CTM-HE and 91.4% of the patients on CCL. 5. There was no statistically significant difference between the two treatment groups in any evaluation described above. The above results suggest that CTM-HE is a useful drug for the treatment of acute tonsillitis at the daily dosage of 600mg (t. i. d.).